Interv Akut Kardiol. 2016;15(2):102-105

Anthracyclines and cardioprotection - focusing on the mechanism of function

Veronika Puchnerová, Zuzana Nováková, Zdeněk Wilhelm
Fyziologický ústav, Lékařská fakulta, Masarykova univerzita, Brno

We can characterize anthracyclines as very important anti-tumour antibiotics with wide range of use in therapy of solid tumours and

haematological diseases. Although anthracyclines are efficient in treatment of cancer, their use is quite limited by their cardiotoxic

effects. In this review we are focusing on the mechanism of function of the drug, the origin of cardiotoxicity and its clinical manifestation.

Then we will be talking about cardioprotection which could eliminate the damage of the heart muscle by the treatment.

Keywords: anthracyclines, cardiotoxicity, doxorubicin, cardioprotection, dexrazoxane

Published: May 9, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Puchnerová V, Nováková Z, Wilhelm Z. Anthracyclines and cardioprotection - focusing on the mechanism of function. Interv Akut Kardiol. 2016;15(2):102-105.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Puma N, Ruggiero A, Ridola V, Maurizi P, Lazzareschi I, Atinna G, Mastrangelo S, De Rosa G, Riccardi R. Anthracycline-related cardiotoxicity: risk factors and therapeutic options in childhood cancers. Signa Vitae 2008; 3(1): 30-34. Go to original source...
    2. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of free trials. Cancer 2003; 11: 2869-2879. Go to original source... Go to PubMed...
    3. Ryberg M, Nielsen D, Cortese G, Nielsen G, Skovsgaard T, Andersen PK. New Insight Into Epirubicin Cardiac Toxicity: Competing Risks Analysis of 1097 Breast Cancer Patients. Journal of the National Cancer Institute 2008; 100(15): 1058-1067. Go to original source... Go to PubMed...
    4. Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 2008; 94: 525-533. Go to original source... Go to PubMed...
    5. Franco VI, Henkel JM, Miller TL, Lipshultz SE. Cardiovascular Effects in Childhood Cancer Survivors Treated with Anthracyclines. Cardiology Research and Practice 2011; Article ID 134679. Go to original source...
    6. Mladosievičová B, et al. Kardioonkologie: 2., přepracované a doplněné vydání. Grada 2014.
    7. Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, Lipshultz SE. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. Journal of Clinical Oncology 1997; 4: 1544-1552. Go to original source... Go to PubMed...
    8. Nysom K, Holm K, Lipsitz SR, Mone SM, Colan SD, Orav EJ, Sallan SE, Olsen JH, Hertz H, Jacobsen JR, Lipshultz SE. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. Journal of Clinical Oncology 1998; 16(2): 545-550. Go to original source... Go to PubMed...
    9. Lipshultz SE, Sanders SP, Colan SD, Goorin AM, Sallan SE, Krischer JP. Monitoring for Anthracycline Cardiotoxicity. Pediatrics 1994; 93(3): 433-437. Go to original source... Go to PubMed...
    10. Lipshultz SE, Lipsitz SR, Mone SM, Goorin AM, Sallan S E, Sanders SP, Orav EJ, Gelber RD, Colan SD. Female Sex and Higher Drug Dose as Risk Factors for Late Cardiotoxic Effects of Doxorubicin Therapy for Childhood Cancer. The New England Journal of Medicine 1995; 332: 1738-1744. Go to original source... Go to PubMed...
    11. Barry E, Alvarez JA, Sculy RE, Miller TL, Lipshultz SE. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Informa Healthcare 2007; 8: 1039-1058. Go to original source... Go to PubMed...
    12. Legha SS, Benjamin RS, Mackay B, Ewer M, Wallace S, Valdivieso M, Rasmussem SL, Blumenschein GR, Freireich EJ. Reduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous Infusion. Annals of Internal Medicine 1982; 96(2): 133-139. Go to original source... Go to PubMed...
    13. Lipshultz SE, Lipsitz SR, Miller TL, Neuberg DS, Dahlberg SE, Colan SD, Silverman LB, Cushman LL, Henkel JM, Sallan SE. Late cardiac status in long-term survivors of childhood high-risk ALL 8 years after continuous or bolus infusion of doxorubicin: The DFCI Childhood ALL 91-01 randomized trial. Journal of Clinical Oncology 2010; 28(15): 9513. Go to original source...
    14. Sieswerda E, Kremer LC, Caron HN, Van Dalen EC. The use of liposomal anthracycline analogues for childhood malignancies: A systematic review. European Journal of Cancer 2011; 47(13): 2000-2008. Go to original source... Go to PubMed...
    15. Gabizon AA, Lyass O, Berry GJ, Wildgust M. Cardiac Safety of Pegylated Liposomal Doxorubicin (Doxil(R)/Caelyx(R)) Demonstrated by Endomyocardial Biopsy in Patients with Advanced Malignancies. Informa Healthcare 2004; 22(5): 663-669. Go to original source... Go to PubMed...
    16. Langer SW. Dexrazoxane for treatment of chemotherapy-related side effects. Cancer Management and Research 2014; 6: 357-363. Go to original source... Go to PubMed...
    17. Herman EH, Mhatre RM, Chadwick DP. Modification of some of the toxic effects of daunomycin (NSC-82,151) by pretreatment with the antineoplastic agent ICRF 159 (NSC-129,943). Toxicology and Applied Pharmacology 2014; 27(3): 517-526. Go to original source... Go to PubMed...
    18. FDA Statement on Dexrazoxane. U.S. Food and Drug Administration 2011. Dostupné online: http://www.fda.gov/Drugs/DrugSafety/ucm263729.htm.
    19. Tebbi CK, London WB, Friedman D, Villaluna D, De Alarcon PA, Constine LS, Mendenhall NP, Sposto R, Chauvenet A, Schwartz CL. Dexrazoxane-Associated Risk for Acute Myeloid Leukemia/Myelodysplastic Syndrome and Other Secondary Malignancies in Pediatric Hodgkin's Disease. Journal of Clinical Oncology 2007; 25(5): 493-500. Go to original source... Go to PubMed...
    20. Quiles JL, Huertas JR, Battino M, Mataix J, Ramirez-Tortosa MC. Antioxidant nutrients and doxorubicin toxicity. Toxicology 2012; 180: 79-95. Go to original source... Go to PubMed...
    21. Shimpo K, Nagatsu T, Yamada K, Sato T, Niimi H, Shamoto M, Takeuchi T, Umezawa H, Fujita K. Ascorbic acid and doxorubicin toxicity. American Journal of Clinical Nutrition 1991; 54: 1298-1301. Go to original source... Go to PubMed...
    22. Traber MG, Packer L. Vitamin E: beyond antioxidant function. American Journal of Clinical Nutrition 1995; 62: 1201-1206. Go to original source... Go to PubMed...
    23. Meyers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K, Young RC. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 1977; 197: 165-167. Go to original source... Go to PubMed...
    24. Wang YM, Madanat FF, Kimball JC, Gleiser CA, Ali MK, Kafuman MW, van Eys J. Effect of vitamin E against adriamycin-induced toxicity in rabbits. Cancer Research 1980; 40: 1022-1027. Go to PubMed...
    25. Boucher F, Coudray C, Tirard V, Barandier C, Tresallet N, Favier A, de Leiris J. Oral selenium supplementation in rats reduces cardiac toxicity of doxorubicin during ischemia and reperfusion. Nutrition 1995; 11: 708-711.
    26. Wouters KA, Kremer LCM, Miller TL, Herman EH, Lipshultz SE. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. British Journal of Haematology 2005; 131: 561-578. Go to original source... Go to PubMed...
    27. Gumulec J, Fojtu M, Raudenska M, Sztalmachova M, Skotakova A, Vlachova J, Skalickova S, Nejdl L, Kopel P, Knopfova L, Adam V, Kizek R, Stiborova M, Babula P, Masarik M. Modulation of Induced Cytotoxicity of Doxorubicin by Using Apoferritin and Liposomal Cages. International Journal of Molecular Sciences 2014; 15(12): 22960-22977. Go to original source... Go to PubMed...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.